AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$SKYE

5AM Partners VII, LLC (DIEKMAN JOHN D, PARMAR KUSH) sold $140K of SKYE (indirect holdings)

5AM Partners VII, LLC sold 375,840 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $0.37 ($0.32–$0.38, $0.14M total) across 9 trades over 2026-08-18 to 2026-08-20. Filed jointly with 5AM Ventures VII, L.P. (10% owner), 5AM Partners II, LLC (10% owner), 5AM Ventures II LP (10% owner), 5AM CO-INVESTORS II LP (10% owner), DIEKMAN JOHN D (10% owner), PARMAR KUSH (10% owner) and ROCKLAGE SCOTT M (10% owner).

Original reporting
SEC EDGAR · 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH, ROCKLAGE SCOTT M
Published Aug 20, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SKYE
Bearish
medium confidence
Mentioned
$SKYE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SKYEBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which can be interpreted as a negative signal, but the amount is small.

02

Market read

Primary source insider sale; modest relevance for traders monitoring SKYE.

03

What to watch

Potential upcoming clinical data releases or financing events not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$SKYEBearishMedium confidence
Context

5AM Partners VII sold 375,840 shares of Skye Bioscience for $140,313, reducing its stake to 7,850,155 shares.

Expected impact

Modest downward pressure in the near term.

Evidence & confidence

Sale size is modest relative to market cap, but insider disposition can influence sentiment.

Market effects

Sector

Minimal impact on biotech sector; typical insider sale activity.

Regional

No significant regional effect.

Global

Limited to investors tracking SKYE.

Counterpoint

What could challenge this read

The sale could be unrelated to fundamentals; may present a buying opportunity if the market overreacts.

Key entities

  • Company
    Skye Bioscience, Inc.

    Biotech firm listed on NASDAQ under ticker SKYE.

  • Insider
    5AM Partners VII, LLC

    Investment firm holding a 10% stake in SKYE.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SKYE insider trading history →

Related articles

AUG 17
$SKYEMedAI 8/10

Skye To Acquire Redx; $125M Financing Secures Path To RXC008 Phase 2 Trial; Stock Up

Skye Bioscience (SKYE) will acquire Redx Pharma via a scheme of arrangement, creating Nasdaq-listed Fibrx Therapeutics led by Redx management. The lead asset is RXC008 for fibrostenotic Crohn’s, with FDA Fast Track and Phase 2 topline data expected in H2 2028. Financing totals $125M, including a $68M PIPE and $36M Series A, funding operations into 2029. SKYE closed at $0.50.

rttnews.com4 min
AUG 14
$SKYEHighAI 9/10

Skye Bioscience, Inc.: Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.

finanznachrichten.de4 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min